Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
Pfizer snapped up a small percentage of Rhythm Pharmaceuticals, which is focused on treating rare genetic disorders that lead to obesity.
AbbVie has acquired an option on an early-stage immuno-oncology drug from biotech company Argenx, giving the U.S. drugmaker access to a treatment with the potential to block a biological pathway that allows cancers to grow. Dutch-Belgian Argenx will receive $40 million upfront from AbbVie for the exclusive option to license ARGX-115 and near-term preclinical milestones […]
